Tuberculosis Research Centre, India
17
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
47%
8 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India
Role: collaborator
MISC COVID-19 Study in Pediatric Population
Role: lead
The Impact of Malnutrition on Immune Responses to Tuberculosis
Role: lead
Preventive Therapy for Tuberculosis in HIV Infected Persons
Role: lead
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
Role: lead
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
Role: lead
BCG Revaccination in Children and Adolescents
Role: lead
Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers
Role: lead
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
Role: lead
Comorbidities and Coinfections in Latent TB
Role: lead
BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots
Role: lead
Latency in Pulmonary Tuberculosis
Role: lead
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Role: lead
Effect of Albendazole Dose on Clearance of Filarial Worms
Role: collaborator
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Role: collaborator
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
Role: lead
Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
Role: lead
All 17 trials loaded